Docetaxel and ovarian cancer

References

• Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Semin. Oncol.34(2 Suppl. 2), S1–S15 (2007).
   PubMed Web of Science ®Google Scholar
• McGuire WP 3rd, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br. J. Cancer89(Suppl. 3), S3–S8 (2003).
   PubMed Web of Science ®Google Scholar
• Gore M, du Bois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J. Clin. Oncol.24(28), 4528–4530 (2006).
   PubMed Web of Science ®Google Scholar
• Group ICON. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet360(9332), 505–515 (2002).
   PubMed Web of Science ®Google Scholar
• Katsumata N. Docetaxel: an alternative taxane in ovarian cancer. Br. J. Cancer89(Suppl. 3), S9–S15 (2003).
   PubMed Web of Science ®Google Scholar
• Sato S, Kigawa J, Kanamori Y et al. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells. Cancer Chemother. Pharmacol.53(3), 247–252 (2004).
   PubMed Web of Science ®Google Scholar
• Guastalla JP 3rd, Dieras V. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br. J. Cancer89(Suppl. 3), S16–S22 (2003).
   PubMed Web of Science ®Google Scholar
• Maenpaa JU. Docetaxel: promising and novel combinations in ovarian cancer. Br. J. Cancer89(Suppl. 3), S29–S34 (2003).
   PubMed Web of Science ®Google Scholar
• Vasey PA. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. J. Clin. Oncol.21(10 Suppl.), 136–144 (2003).
   Google Scholar
• Markman M, Zanotti K, Webster K, Peterson G, Kulp B, Belinson J. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol. Oncol.91(3), 573–576 (2003).
   PubMed Web of Science ®Google Scholar
• Niwa Y, Nakanishi T, Kuzuya K, Nawa A, Mizutani S. Salvage treatment with docetaxel for recurrent epithelial ovarian cancer. Int. J. Clin. Oncol.8(6), 343–347 (2003).
   PubMedGoogle Scholar
• Berkenblit A, Seiden MV, Matulonis UA et al. A Phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol. Oncol.95(3), 624–631 (2004).
   PubMed Web of Science ®Google Scholar
• Terauchi F, Hirano T, Taoka H et al. Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a Phase I study. Int. J. Clin. Oncol.8(6), 348–351 (2003).
   PubMedGoogle Scholar
• Komiyama S, Tsuji H, Asai S, Dokoh J, Ishikawa M, Mikami M. A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer. Eur. J. Gynaecol. Oncol.26(3), 299–302 (2005).
   PubMed Web of Science ®Google Scholar
• Tinker AV, Gebski V, Fitzharris B et al. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel – ANZGOG 02–01. Gynecol. Oncol.104(3), 647–653 (2007).
   PubMed Web of Science ®Google Scholar
• Morgan RJ Jr, Doroshow JH, Synold T et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin. Cancer Res.9(16 Pt 1), 5896–5901 (2003).
   PubMed Web of Science ®Google Scholar
• de Bree E, Theodoropoulos PA, Rosing H et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat. Rev.32(6), 471–482 (2006).
   PubMed Web of Science ®Google Scholar
• Strauss HG, Henze A, Teichmann A et al. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Gynecol. Oncol.104(3), 612–616 (2007).
   PubMed Web of Science ®Google Scholar
• Kushner D, Connor J, Sanchez F et al. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a Phase II trial. Gynecol. Oncol.105(2), 358–364 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Ludovisi M, De Vincenzo R et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a Phase II study. Ann. Oncol.18(8), 1348–1353 (2007).
   PubMed Web of Science ®Google Scholar
• Vasey PA, Atkinson R, Osborne R et al. SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer. Br. J. Cancer94(1), 62–68 (2006).
   PubMed Web of Science ®Google Scholar
• Clamp AR, Maenpaa J, Cruickshank D et al. SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. Br. J. Cancer94(1), 55–61 (2006).
   PubMed Web of Science ®Google Scholar
• Pfisterer J, du Bois A, Wagner U et al. Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A Phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Gynecol. Oncol.92(3), 949–956 (2004).
   PubMed Web of Science ®Google Scholar
• Vorobiof DA, Rapoport BL, Chasen MR, Cohen GL, Mahomed R, Karime M. Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy. Int. J. Gynecol. Cancer13(3), 287–291 (2003).
   PubMed Web of Science ®Google Scholar
• Minagawa Y, Kigawa J, Kanamori Y et al. Feasibility study comparing docetaxel–cisplatin versus docetaxel–carboplatin as first-line chemotherapy for ovarian cancer. Gynecol. Oncol.101(3), 495–498 (2006).
   PubMed Web of Science ®Google Scholar
• Dieras V, Guastalla JP, Ferrero JM et al. A multicenter Phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study. Cancer Chemother. Pharmacol.53(6), 489–495 (2004).
   PubMed Web of Science ®Google Scholar
• Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst.96(22), 1682–1691 (2004).
   PubMed Web of Science ®Google Scholar
• Lemenager M, Lecomte S, Bonneterre M, Bessa E, Dauba J, Bonneterre J. Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Eur. J. Cancer33(2), 297–300 (1997).
   PubMed Web of Science ®Google Scholar
• Andre F, Hatzis C, Anderson K et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin. Cancer Res.13(7), 2061–2067 (2007).
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med.354(1), 34–43 (2006).
   PubMed Web of Science ®Google Scholar